Surgery Partners

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Surgery Partners reports robust Q4 earnings, eyes growth in cardiac care

Surgery Partners' strong financial performance, driven by strategic initiatives and revenue growth, positions the company for continued success. While facing challenges in adoption rates and reimbursement, the company's focus on outpatient care and higher acuity service lines presents growth opportunities. With a proactive approach to recruitment and expansion, Surgery Partners is poised for a positive trajectory in 2023.

Surgery Partners (SGRY) posts robust Q1 results, eyes strategic growth

Surgery Partners (SGRY) delivered strong financial performance, operational efficiency, and strategic growth initiatives in Q1 2023.
Despite challenges from revenue timing and minimal earnings impact in the short term, the company's disciplined approach and focus on partnerships and acquisitions offer promising opportunities.
With a raised adjusted EBITDA outlook, a commitment to excellence, and a clear growth strategy, Surgery Partners is well-positioned for continued success and value creation.

Surgery Partners exceeds Q2 expectations, eyes strategic growth opportunities

Surgery Partners delivered strong financial performance in Q2 2023, surpassing expectations and demonstrating resilience in surgical case growth.
Despite challenges in anesthesia coverage and subsidies, the company remains optimistic about its growth prospects and is focused on operational efficiencies.
Strategic investments in orthopedics and cardiology, along with a commitment to high-quality care, underscore Surgery Partners' long-term growth potential.

Surgery Partners beats Q3 targets, eyes mid-teens growth in 2024

Surgery Partners exceeded Q3 expectations, showcasing strong performance and strategic initiatives. While facing challenges from portfolio adjustments and regulatory proposals, the company is well-positioned for continued growth through acquisitions and focus on high acuity cases.

Surgery Partners (SGRY) reports robust 2023 results and eyes strategic growth in 2024

Surgery Partners (SGRY) delivered strong financial performance in 2023, with a positive outlook for 2024. The company's focus on margin expansion, growth in higher acuity procedures, and strategic acquisitions positions it well for continued success. Challenges include cash flow uncertainties and the impact of unique comp dynamics on case growth.

Surgery Partners (SGRY) reports robust Q1 earnings and eyes strategic acquisitions for continued growth

Surgery Partners (SGRY) delivered strong financial results in Q1 2024, showcasing solid revenue growth and margin expansion. The company's strategic focus on acquisitions, margin improvement initiatives, and effective cost management underpin its optimistic outlook for sustained growth and cash flow generation.

Surgery Partners (SGRY) posts impressive Q2 results, raises full-year outlook

Surgery Partners (SGRY) delivered strong financial performance in Q2 2024, driven by revenue growth, enhanced margins, and strategic acquisitions. Despite facing leverage challenges, the company's focus on specialty physician recruitment and operational efficiency presents opportunities for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BRENTWOOD, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the fourth quarter and full year ended December 31, 2023.

Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2023 Results; Sets 2024 Guidance

Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Gear Up for Surgery Partners (SGRY) Q4 Earnings: Wall Street Estimates for Key Metrics

BRENTWOOD, Tenn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2023 results before the market opens on Monday, February 26, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces Fourth Quarter 2023 Earnings Release Date and Conference Call Details

Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Surgery Partners (SGRY) is Poised to Beat Earnings Estimates Again

CHICAGO--(BUSINESS WIRE)--Oral Surgery Partners (“OSP”), an established and rapidly-growing oral surgery management group backed by Sheridan Capital Partners (“SCP”), announced today the closing of a $400+ million credit expansion to build on existing success in partnership with funds managed by Neuberger Berman and Aquarian Investments. With this additional capital, OSP will continue investing in infrastructure and pursuing add-on acquisitions and partnerships nationwide. Since investing in 20.

Sheridan Capital Partners-Backed Oral Surgery Partners Announces $400M Credit Expansion, Multiple Acquisitions, and C-Suite Hires

Surgery Partners Inc. NASDAQ: SGRY is a leading healthcare services provider that owns and operates over 180 outpatient surgical centers in 31 states. Its integrated delivery model includes surgical facilities and ancillary services comprised of anesthesia services and multi-specialty physician groups.

Surgery Partners feeling no pinch from macroeconomic weakness

BRENTWOOD, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 8, 2024, as part of the 42nd Annual J.P. Morgan Healthcare Conference, including a presentation at 5:15 p.m. ET. Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion. Additionally, consistent with managements commitment to driving mid-teens growth, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.

Surgery Partners, Inc. Reaffirms 2023 Full Year Guidance and Provides 2024 Initial Adjusted EBITDA Outlook

BRENTWOOD, Tenn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced that Eric Evans, Chief Executive Officer and Dave Doherty, Chief Financial Officer will meet with investors at the J.P. Morgan Healthcare Conference, including a presentation on Monday, January 8, 2024 at 5:15p.m. (Eastern Time).

Surgery Partners, Inc. to Present at Upcoming Investor Conference

BRENTWOOD, Tenn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (Nasdaq: SGRY) (“Surgery Partners” or the “Company”) today announced that certain of the Company's stockholders (the “Selling Stockholders”) intend to offer for sale in an underwritten secondary offering (the “Offering”) 8,000,000 shares of the Company's common stock, par value $0.01 per share. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Surgery Partners, Inc. Announces Proposed Secondary Offering of Common Stock

BRENTWOOD, Tenn., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced today that Surgery Center Holdings, Inc., a wholly owned subsidiary of the Company, has received commitments for a new $1.4 billion senior secured term loan (the “New Term Loan”). Upon closing (such date, the “Closing Date”), the new Term Loan will bear interest at a rate equal to 3.50% per annum in excess of the applicable Secured Overnight Financing Rate (SOFR) index rate (or, at the option of the Company, 2.50% per annum in excess of an adjusted base rate), will mature on the date that is seven years after the Closing Date and will be subject to customary terms and conditions. Additionally, the Company expects to refinance and increase its existing revolving credit facility with a new senior secured revolving credit facility in an aggregate principal amount of approximately $703.75 million (together with the New Term Loan, the “New Credit Facilities”) that matures five years after the Closing Date, on customary terms and conditions.

Surgery Partners, Inc. Completes Refinancing Transaction

Surgery Partners, Inc. (SGRY) Q3 2023 Earnings Call Transcript

The headline numbers for Surgery Partners (SGRY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Surgery Partners (SGRY) Q3 Earnings: A Look at Key Metrics

BRENTWOOD, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading operator of surgical facilities, today announced financial results for the third quarter ended September 30, 2023.

Surgery Partners, Inc. Announces Third Quarter 2023 Results

Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?

CHICAGO--(BUSINESS WIRE)--Sheridan Capital Partners (“Sheridan”) announced today the formation of Ascend Plastic Surgery Partners (“Ascend” or the “Company”), a plastic surgery physician practice management company. Today, Ascend represents the combination of five plastic surgery practices and two standalone MedSpas. Sheridan invested alongside Ascend's surgeons and management, who have retained a meaningful ownership stake in the business. Ascend is headquartered in Atlanta, Georgia, and curre.

Sheridan Capital Partners Announces Formation of Ascend Plastic Surgery Partners

BRENTWOOD, Tenn., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2023 results before the market opens on Tuesday, November 7, 2023, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces Third Quarter 2023 Earnings Release Date and Conference Call Details

HealthEquity

Medpace Holdings

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most.

3 Medical Services Stocks Countering Industry-Wide Headwinds

Surgery Partners (SGRY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -22.17% in 4 Weeks, Here's Why Surgery Partners (SGRY) Looks Ripe for a Turnaround

Surgery Partners, Inc. (NASDAQ:SGRY ) Q2 2023 Earnings Conference Call August 1, 2023 8:30 AM ET Company Participants Dave Doherty - CFO Wayne DeVeydt - Executive Chairman Eric Evans - CEO Conference Call Participants Jason Cassorla - Citigroup Kevin Fischbeck - Bank of America Gary Taylor - Cowen Brian Tanquilut - Jefferies Whit Mayo - Leerink Partners Lisa Gill - JPMorgan Operator Good morning, and welcome to the Surgery Partners Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Surgery Partners, Inc. (SGRY) Q2 2023 Earnings Call Transcript

Although the revenue and EPS for Surgery Partners (SGRY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Surgery Partners (SGRY) Q2 Earnings: A Look at Key Metrics

Surgery Partners (SGRY) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to loss of $0.03 per share a year ago.

Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates

BRENTWOOD, Tenn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced financial results for the second quarter ended June 30, 2023.

Surgery Partners, Inc. Announces Second Quarter 2023 Results

BRENTWOOD, Tenn., July 19, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2023 results before the market opens on Tuesday, August 1, 2023, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces Second Quarter 2023 Earnings Release Date and Conference Call Details

Centene

HCA Healthcare

Humana

Tenet Healthcare

Universal Health Services

UnitedHealth Group

Recent growth in inpatient and outpatient services has been even higher than elevated investor expectations, Mizuho Securities analysts said in a research note Tuesday. Outpatient volume grew 8% in the second quarter, compared with the year-earlier period, while inpatient volume grew 4%, according to a Mizuho survey of more than 200 doctors in 14 specialties.

Healthcare demand outpacing investor expectations, boosting outlook for providers, Mizuho analysts say

Surgery Partners comes with a set of attractive investment criteria. SGRY's economic characteristics, such as a consistent stream of 20% returns on existing capital, are standout features in the debate. A revised growth outlook and attractive valuation support a buy rating with a $62.50 price target.

News for Surgery Partners Stock (SGRY)